Efficacy of Phase I and Phase II Coxiella burnetii Bacterin Vaccines in a Pregnant Ewe Challenge Model

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Efficacy of Phase I and Phase II Coxiella burnetii Bacterin Vaccines in a Pregnant Ewe Challenge Model. / Williams-Macdonald, Sarah E.; Mitchell, Mairi; Frew, David; Palarea-Albaladejo, Javier; Ewing, David; Golde, William T.; Longbottom, David; Nisbet, Alasdair J.; Livingstone, Morag; Hamilton, Clare M.; Fitzgerald, Stephen F.; Buus, Søren; Bach, Emil; Dinkla, Annemieke; Roest, Hendrik-Jan; Koets, Ad P.; McNeilly, Tom N.

I: Vaccines, Bind 11, Nr. 3, 511, 2023.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Williams-Macdonald, SE, Mitchell, M, Frew, D, Palarea-Albaladejo, J, Ewing, D, Golde, WT, Longbottom, D, Nisbet, AJ, Livingstone, M, Hamilton, CM, Fitzgerald, SF, Buus, S, Bach, E, Dinkla, A, Roest, H-J, Koets, AP & McNeilly, TN 2023, 'Efficacy of Phase I and Phase II Coxiella burnetii Bacterin Vaccines in a Pregnant Ewe Challenge Model', Vaccines, bind 11, nr. 3, 511. https://doi.org/10.3390/vaccines11030511

APA

Williams-Macdonald, S. E., Mitchell, M., Frew, D., Palarea-Albaladejo, J., Ewing, D., Golde, W. T., Longbottom, D., Nisbet, A. J., Livingstone, M., Hamilton, C. M., Fitzgerald, S. F., Buus, S., Bach, E., Dinkla, A., Roest, H-J., Koets, A. P., & McNeilly, T. N. (2023). Efficacy of Phase I and Phase II Coxiella burnetii Bacterin Vaccines in a Pregnant Ewe Challenge Model. Vaccines, 11(3), [511]. https://doi.org/10.3390/vaccines11030511

Vancouver

Williams-Macdonald SE, Mitchell M, Frew D, Palarea-Albaladejo J, Ewing D, Golde WT o.a. Efficacy of Phase I and Phase II Coxiella burnetii Bacterin Vaccines in a Pregnant Ewe Challenge Model. Vaccines. 2023;11(3). 511. https://doi.org/10.3390/vaccines11030511

Author

Williams-Macdonald, Sarah E. ; Mitchell, Mairi ; Frew, David ; Palarea-Albaladejo, Javier ; Ewing, David ; Golde, William T. ; Longbottom, David ; Nisbet, Alasdair J. ; Livingstone, Morag ; Hamilton, Clare M. ; Fitzgerald, Stephen F. ; Buus, Søren ; Bach, Emil ; Dinkla, Annemieke ; Roest, Hendrik-Jan ; Koets, Ad P. ; McNeilly, Tom N. / Efficacy of Phase I and Phase II Coxiella burnetii Bacterin Vaccines in a Pregnant Ewe Challenge Model. I: Vaccines. 2023 ; Bind 11, Nr. 3.

Bibtex

@article{ac9a2a45fb67407db18070acc8b447cf,
title = "Efficacy of Phase I and Phase II Coxiella burnetii Bacterin Vaccines in a Pregnant Ewe Challenge Model",
abstract = "The bacterium Coxiella burnetii can cause the disease Q-fever in a wide range of animal hosts. Ruminants, including sheep, are thought to play a pivotal role in the transmission of C. burnetii to humans; however, the only existing livestock vaccine, namely, Coxevac{\textregistered} (Ceva Animal Health Ltd., Libourne, France), a killed bacterin vaccine based on phase I C. burnetii strain Nine-Mile, is only approved for use in goats and cattle. In this study, a pregnant ewe challenge model was used to determine the protective effects of Coxevac{\textregistered} and an experimental bacterin vaccine based on phase II C. burnetii against C. burnetii challenge. Prior to mating, ewes (n = 20 per group) were vaccinated subcutaneously with either Coxevac{\textregistered}, the phase II vaccine, or were unvaccinated. A subset of pregnant ewes (n = 6) from each group was then challenged 151 days later (~100 days of gestation) with 106 infectious mouse doses of C. burnetii, Nine-Mile strain RSA493. Both vaccines provided protection against C. burnetii challenge as measured by reductions in bacterial shedding in faeces, milk and vaginal mucus, and reduced abnormal pregnancies, compared to unvaccinated controls. This work highlights that the phase I vaccine Coxevac{\textregistered} can protect ewes against C. burnetii infection. Furthermore, the phase II vaccine provided comparable levels of protection and may offer a safer and cost-effective alternative to the currently licensed vaccine.",
keywords = "Coxiella burnetii, phase I, phase II, Q-fever, sheep, vaccine",
author = "Williams-Macdonald, {Sarah E.} and Mairi Mitchell and David Frew and Javier Palarea-Albaladejo and David Ewing and Golde, {William T.} and David Longbottom and Nisbet, {Alasdair J.} and Morag Livingstone and Hamilton, {Clare M.} and Fitzgerald, {Stephen F.} and S{\o}ren Buus and Emil Bach and Annemieke Dinkla and Hendrik-Jan Roest and Koets, {Ad P.} and McNeilly, {Tom N.}",
note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",
year = "2023",
doi = "10.3390/vaccines11030511",
language = "English",
volume = "11",
journal = "Vaccines",
issn = "2076-393X",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

RIS

TY - JOUR

T1 - Efficacy of Phase I and Phase II Coxiella burnetii Bacterin Vaccines in a Pregnant Ewe Challenge Model

AU - Williams-Macdonald, Sarah E.

AU - Mitchell, Mairi

AU - Frew, David

AU - Palarea-Albaladejo, Javier

AU - Ewing, David

AU - Golde, William T.

AU - Longbottom, David

AU - Nisbet, Alasdair J.

AU - Livingstone, Morag

AU - Hamilton, Clare M.

AU - Fitzgerald, Stephen F.

AU - Buus, Søren

AU - Bach, Emil

AU - Dinkla, Annemieke

AU - Roest, Hendrik-Jan

AU - Koets, Ad P.

AU - McNeilly, Tom N.

N1 - Publisher Copyright: © 2023 by the authors.

PY - 2023

Y1 - 2023

N2 - The bacterium Coxiella burnetii can cause the disease Q-fever in a wide range of animal hosts. Ruminants, including sheep, are thought to play a pivotal role in the transmission of C. burnetii to humans; however, the only existing livestock vaccine, namely, Coxevac® (Ceva Animal Health Ltd., Libourne, France), a killed bacterin vaccine based on phase I C. burnetii strain Nine-Mile, is only approved for use in goats and cattle. In this study, a pregnant ewe challenge model was used to determine the protective effects of Coxevac® and an experimental bacterin vaccine based on phase II C. burnetii against C. burnetii challenge. Prior to mating, ewes (n = 20 per group) were vaccinated subcutaneously with either Coxevac®, the phase II vaccine, or were unvaccinated. A subset of pregnant ewes (n = 6) from each group was then challenged 151 days later (~100 days of gestation) with 106 infectious mouse doses of C. burnetii, Nine-Mile strain RSA493. Both vaccines provided protection against C. burnetii challenge as measured by reductions in bacterial shedding in faeces, milk and vaginal mucus, and reduced abnormal pregnancies, compared to unvaccinated controls. This work highlights that the phase I vaccine Coxevac® can protect ewes against C. burnetii infection. Furthermore, the phase II vaccine provided comparable levels of protection and may offer a safer and cost-effective alternative to the currently licensed vaccine.

AB - The bacterium Coxiella burnetii can cause the disease Q-fever in a wide range of animal hosts. Ruminants, including sheep, are thought to play a pivotal role in the transmission of C. burnetii to humans; however, the only existing livestock vaccine, namely, Coxevac® (Ceva Animal Health Ltd., Libourne, France), a killed bacterin vaccine based on phase I C. burnetii strain Nine-Mile, is only approved for use in goats and cattle. In this study, a pregnant ewe challenge model was used to determine the protective effects of Coxevac® and an experimental bacterin vaccine based on phase II C. burnetii against C. burnetii challenge. Prior to mating, ewes (n = 20 per group) were vaccinated subcutaneously with either Coxevac®, the phase II vaccine, or were unvaccinated. A subset of pregnant ewes (n = 6) from each group was then challenged 151 days later (~100 days of gestation) with 106 infectious mouse doses of C. burnetii, Nine-Mile strain RSA493. Both vaccines provided protection against C. burnetii challenge as measured by reductions in bacterial shedding in faeces, milk and vaginal mucus, and reduced abnormal pregnancies, compared to unvaccinated controls. This work highlights that the phase I vaccine Coxevac® can protect ewes against C. burnetii infection. Furthermore, the phase II vaccine provided comparable levels of protection and may offer a safer and cost-effective alternative to the currently licensed vaccine.

KW - Coxiella burnetii

KW - phase I

KW - phase II

KW - Q-fever

KW - sheep

KW - vaccine

U2 - 10.3390/vaccines11030511

DO - 10.3390/vaccines11030511

M3 - Journal article

C2 - 36992095

AN - SCOPUS:85151565089

VL - 11

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 3

M1 - 511

ER -

ID: 371612628